Breast Cancer — Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Citation(s)
A Multicentre, Randomised Phase II to Compare Epirubicin (E) & Cyclophosphamide (C) Treatment Plus Docetaxel (D) & Trastuzumab vs. E & C Treatment Plus D & Lapatinib in Women With Primary Resectable or Locally Advanced HER2+ Breast Cancer